Immunovant Files 8-K with Regulatory Updates

Ticker: IMVT · Form: 8-K · Filed: Sep 9, 2024 · CIK: 1764013

Sentiment: neutral

Topics: 8-K, regulatory-filing, financials

Related Tickers: IMVT

TL;DR

IMVT filed an 8-K on 9/9/24 covering Reg FD, other events, and financials.

AI Summary

Immunovant, Inc. filed an 8-K on September 9, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, formerly known as Health Sciences Acquisitions Corp, is incorporated in Delaware and has its principal executive offices in New York, NY.

Why It Matters

This 8-K filing provides important updates and disclosures from Immunovant, Inc. to investors and the public regarding its corporate activities and financial reporting.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Immunovant, Inc.?

The 8-K filing serves to report on Regulation FD disclosures, other events, and financial statements and exhibits for Immunovant, Inc.

When was this 8-K report filed?

This 8-K report was filed on September 9, 2024.

What was Immunovant, Inc.'s former company name?

Immunovant, Inc.'s former company name was Health Sciences Acquisitions Corp.

In which U.S. state is Immunovant, Inc. incorporated?

Immunovant, Inc. is incorporated in Delaware.

Where are Immunovant, Inc.'s principal executive offices located?

Immunovant, Inc.'s principal executive offices are located at 320 West 37th Street, New York, NY 10018.

Filing Stats: 598 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2024-09-09 07:40:38

Key Financial Figures

Filing Documents

01. Regulation FD Disclo sure

Item 7.01. Regulation FD Disclo sure. On September 9, 2024, Immunovant, Inc. (the "Company") issued a press release providing an update on its Graves' Disease ("GD") development program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01. Other Events

Item 8.01. Other Events. As described in the press release, the Company will host a conference call and webcast to discuss the results of the GD trial at 8:00 a.m. ET on September 9, 2024. A copy of the presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated September 9, 2024. 99.2 Presentation, dated September 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Eva Renee Barnett Eva Renee Barnett Chief Financial Officer Date: September 9, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing